A Phase 1 Open Label Multi-Arm Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Solid Tumors
  • Age: Between 18 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Dose Escalation Phase participants: Have any histologically- or cytologically- confirmed advanced/metastatic solid tumor by pathology report and have received, have been intolerant to, or have been ineligible for all treatment known to confer clinical benefit. Solid tumors of any type are eligible for enrollment. 2. Have measurable disease by RECIST 1.1 as assessed by the local site investigator/radiology. Target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. 3. Expansion phase participants: Have a histologically or cytologically-documented, advanced (metastatic and/or unresectable) solid tumor of specific tumor indication as shown in the table below and fulfill cohort-specific requirements regarding prior (line of therapy) treatments.

You may not be eligible for this study if the following are true:

  • 1. Has had chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2 weeks for palliative radiation) prior to the first dose of study therapy, or has not recovered to NCI CTCAE version 4 Grade 1 or better from any AEs that were due to cancer therapeutics administered more than 4 weeks earlier (this includes participants with previous immunomodulatory therapy with residual immune-related AEs [irAEs]). 2. Has not recovered from all radiation-related toxicities to Grade 1 or less, requires corticosteroids, and had radiation pneumonitis. 3. Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.